Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697463 · ClinicalTrials.gov registry record · Phase 2
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00697463 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 22 participants.
The verdict
NCT00697463, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young individuals sustain one or more low-trauma fractures. Teriparatide \[PTH(1-34)\], which is FDA approved for treatment of osteoporosis in men and postmenopausal women, works by stimulating bone formation. The investigators hypothesize that teriparatide will significantly increase bone density (BMD) and improve bone structure in premenopausal women with IOP.
Interventions
- DRUG Teriparatide (PTH 1-34)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-08-20 |
| Est. Completion | 2012-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697463
The ClinicalTrials.gov registry entry for NCT00697463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Teriparatide (PTH 1-34) is the first listed.
NCT00697463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00697463 about?
NCT00697463 is a clinical study titled "Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women". Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young individuals sustain one or more low-trauma fractures. Teriparatide \[PTH(1-34)\], which is FDA approved for treatment of osteoporosis in men and postmenopausal women, works by stimulating bone formation. The inves...
What is the current status of trial NCT00697463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2008-08-20. Estimated completion is 2012-01-03.
What interventions are being tested in trial NCT00697463?
The interventions under investigation include: Teriparatide (PTH 1-34) (DRUG).
Who is sponsoring clinical trial NCT00697463?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.